Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stromal Cells Protect Cardiac Cells Against Hypoxia/Reoxygenation Injury by Inhibiting Endoplasmic Reticulum Stress via Activation of the PI3K/Akt Pathway

Changyi Zhang¹, Hongwu Wang², Godfrey C.F. Chan³, Yu Zhou⁴, Xiulan Lai⁵, and Ma Lian²,⁶

Abstract
Endoplasmic reticulum (ER) stress is implicated in the pathogenesis of many diseases, including myocardial ischemia/reperfusion injury. We hypothesized that human umbilical cord mesenchymal stromal cells derived extracellular vesicles (HuMSC-EVs) could protect cardiac cells against hyperactive ER stress induced by hypoxia/reoxygenation (H/R) injury. The H/R model was generated using the H9c2 cultured cardiac cell line. HuMSC-EVs were extracted using a commercially available exosome isolation reagent. Levels of apoptosis-related signaling molecules and the degree of ER stress were assessed by western blot. The role of the PI3K/Akt pathway was investigated using signaling inhibitors. Lactate dehydrogenase leakage and 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) analysis were used for evaluating the therapeutic effects of HuMSC-EVs in vitro. The results showed that ER stress and the rate of apoptosis were increased in the context of H/R injury. Treatment with HuMSC-EVs inhibited ER stress and increased survival in H9c2 cells exposed to H/R. Mechanistically, the PI3K/Akt pathway was activated by treatment with HuMSC-EVs after H/R. Inhibition of the PI3K/Akt pathway by a specific inhibitor, LY294002, partially reduced the protective effect of HuMSC-EVs. Our findings suggest that HuMSC-EVs could alleviate ER stress–induced apoptosis during H/R via activation of the PI3K/Akt pathway.

Keywords
human umbilical cord mesenchymal stromal cells, extracellular vesicles, hypoxia/reoxygenation injury, ER stress
**Introduction**

Acute myocardial infarction is a significant cause of mortality worldwide. While timely reperfusion, such as primary percutaneous coronary intervention, has proven to be an invaluable therapy, subsequent reperfusion induces further cardiac damage during a process known as myocardial ischemia/reperfusion (MI/R) injury. The mechanisms underlying I/R injury appear to be multifactorial, including elevated oxidative stress, intracellular Ca\(^{2+}\) overload, and endoplasmic reticulum (ER) stress. The ER is the main organelle responsible for the regulation of intracellular homeostasis (including the translocation and post-transcriptional modification of proteins), lipid synthesis, calcium homeostasis, normal cell function, and survival. Perturbations to any of these processes can result in a large proportion of proteins that are misfolded and accumulate inside the ER lumen, resulting in ER stress. The activation of intracellular signal transduction pathways by ER stress is defined as the unfolded protein response (UPR). Activation of the UPR triggers an adaptive program designed to restore homeostasis by increasing the folding capacity of the cell, reducing protein synthesis, and enhancing the clearance of abnormally folded proteins and damaged organelles. But excessive ER stress induces apoptosis. Previous studies revealed that ER stress–initiated apoptosis plays a very important role in MI/R injury. Therefore, ER stress, as a potential target for the treatment of I/R-induced myocardial injury, has been an area of extensive research.

Mesenchymal stromal cells (MSCs) are present in a variety of tissues such as adipose tissue, peripheral blood, bone marrow, and umbilical cord. This type of cell has been shown to protect against I/R injury through several mechanisms including immunomodulation, as well as anti-apoptotic and proangiogenic effects. Among these sources, human umbilical cord mesenchymal stromal cells (HuMSCs) are more suitable for replacement therapy because of fewer ethical issues, low immunogenicity, and high capacity for self-renewal. Our group and others previously reported the potential therapeutic effect of HuMSCs in the treatment of cardiac injury. Although transplanted MSCs exhibited low survival in the host, and only a small percentage of transplanted MSCs were able to reach the target site, MSCs transplantation has been shown to work well under certain conditions, primarily owing to the paracrine capability. Extracellular vesicles (EVs) are small, membrane-bound nanovesicles that range in size from 50 to 200 nm and contain nucleic acids, proteins, and bioactive lipids. Several lines of evidence suggest that exosomes are active paracrine elements that play an important role in cell-to-cell communication. Exosomes therefore have great potential to promote tissue repair. Recently, Wang et al. reported that exosomes derived from bone marrow mesenchymal stem cells protect against renal I/R injury by inhibiting ER stress. However, the relationships of HuMSC-derived extracellular vesicles (HuMSC-EVs) to MI/R injury and ER stress–induced apoptosis are unknown.

In this study, we used an *in vitro* hypoxia/reoxygenation (H/R) injury system to investigate whether HuMSC-EVs protects against MI/R injury through the regulation of ER stress.

**Materials and Methods**

**Cell Culture**

HuMSCs were isolated as previously described. The study protocol was approved by the Institutional Review Board of Shantou University Medical College (Shantou, China). A total of six patients provided HuMSC. All patients provided signed informed consent. HuMSCs were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F12 media containing 10% exosome-depleted fetal bovine serum (Ca #C38010050, Viva-Cell Biosciences, Shanghai, China) in an incubator held at 37°C and filled with 5% CO\(_2\). The third passage of HuMSCs was used for exosome extraction. H9c2 cardiac cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA), then cultured in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 U/ml penicillin, in an incubator held at 37°C and filled with 5% CO\(_2\). The PI3K/Akt inhibitor (LY294002) was purchased from Sigma-Aldrich (St. Louis, MO, USA).

**Extraction and Identification of HuMSC-EVs**

HuMSC-EVs were isolated using ExoQuick-TC (System Biosciences, Palo Alto, CA, USA), according to the manufacturer’s protocol. Purified HuMSC-EVs were identified by transmission electron microscopy (JEOL JEM 1230; Tokyo, Japan). Exosomal markers such as CD63 and CD9 were analyzed by western blot and flow cytometry. Nanoparticle tracking analysis (NTA) was performed to analyze the exosome particles using a Nanoparticle Tracking Analyzer (ZetaView, PMX, Meerbusch, Germany). The protein concentration of the purified exosome fraction was measured with a bicinchoninic acid (BCA) protein assay kit (ThermoFisher Scientific, Waltham, MA, USA).

**Internalization of HuMSC-EVs by H9c2 Cells**

HuMSC-EVs were incubated with PKH26 (Ca#MIDI26, Sigma-Aldrich, Shanghai, China) for 15 min at 37°C in the dark and washed three times in 1 × phosphate buffered saline with centrifugation at 100,000 × g, followed by incubation at 4°C for 2 h. The purified EVs were then added to the culture medium and incubated with H9c2 cells for 12 h. Cell nuclei were labeled with 4’,6-diamidino-2-phenylindole (Ca#C1005, Beyotime Biotechnology, Shanghai, China). The uptake of HuMSC-EVs by H9c2 cells was analyzed using Olympus BX51 confocal microscopy (Olympus, Tokyo, Japan).
Generation of the H/R Model

To generate oxygen-glucose deprivation (OGD), the initial culture medium was replaced with buffer [pH 6.2, 137 mM NaCl, 12 mM KCl, 0.49 mM MgCl2·6H2O, 0.9 mM CaCl2, 4 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, and 20 mM Na lactate] to generate OGD. Then, H9c2 cells were exposed to pure N2 gas at 37°C for 3 h. H9c2 cells were then reoxygentized in fresh oxygenated culture medium for 1 h, in an incubator with 5% CO2. Four experimental groups were designed as follows: normal group, in which H9c2 cells were cultured under normal conditions; H/R group; H/R + HuMSC-EVs group, in which H9c2 cells were first cultured with HuMSC-EVs (8 μg/ml) for 12 h, followed by exposure to H/R; and H/R + HuMSC-EVs + LY group, in which the PI3 K inhibitor LY294002 was added to cells at a concentration of 15 μmol/l for 30 min before H/R.

Cell Viability Assay

H9c2 cell viability was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay. After exposure to H/R, MTT was added to the culture medium for incubation for 4 h at 37°C. MTT was then solubilized with 150 μl dimethyl sulfoxide. The optical density (OD) values were determined at 490 nm by a microplate reader. Relative cell viability was calculated as a percentage, as follows: viability (%) = (OD of assay − OD of blank)/(OD of control − OD of blank) × 100%. The experiment was repeated three times.

Assay of Lactate Dehydrogenase Activity

To determine the extent of cell injury induced by H/R injury, lactate dehydrogenase (LDH) activity in culture media was measured using a lactate dehydrogenase activity assay kit (Uscn Life Science, Wuhan, China), according to the manufacturer’s protocol. The experiment was repeated three times.

Western Blot

H9c2 cells or HuMSC-EVs were lysed in RIPA lysis buffer, followed by whole-protein purification. Protein concentrations were quantified using the BCA method (Beyotime Institute of Biotechnology, Haimen, China). Total protein (30 μg) was subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred electrophoretically to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). Membranes were incubated with the primary antibody of interest for 16 h at 4°C, followed by incubation with horseradish peroxidase–conjugated goat anti-rabbit immunoglobulin G secondary antibody (1:2,000, Ca# BE0101, EASYBIO, Beijing, China) for 1 h at room temperature. Specific protein bands were observed with an ECL Plus chemiluminescence kit (EMD Millipore) and quantitatively analyzed with Image Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

The primary antibodies used in this study were: CD9 (1:2,000, Ca#ab92726, Abcam, Cambridge, MA, USA); CD63 (1:1,000, Ca#ab134045, Abcam); Bax (1:5,000, Ca#ab32503, Abcam); bcl2 (1:2,000, Ca#ab196495, Abcam); cleaved-caspase 3 (1:1,000, Ca#9661, CST, Danvers, MA, USA); glucose-regulated protein 78 (GRP78; 1:1,000, Ca#3183, CST); C/EBP homologous protein (CHOP; 1:1,000, Ca#2895, CST); inositol-requiring protein 1α (IRE1α; 1:1,000, Ca#3294, CST); activating transcription factor 6 (ATF6; 1:1,000, Ca#ab203119, Abcam); Akt (1:1,000, Ca#4685, CST); p-Akt (1:1,000, Ca#4060, CST); PI3 K (1:1,000, Ca#4257, CST); and β-actin (1:5,000, Ca#0021, EASYBIO). The experiment was repeated three times.

Statistical Analysis

All statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, USA). Data are expressed as means ± standard deviation. Statistical differences between groups were assessed with one-way analysis of variance, followed by Tukey’s multiple comparison test. A P-value <0.05 was considered statistically significant.

Results

Characterization of HuMSC-EVs

We characterized the HuMSC-EVs by transmission electron microscopy, which revealed the presence of spherical vesicles in the HuMSC-EVs isolated (Fig. 1A). The concentration of exosomes was 5.4 × 10^9 particles/ml. Particle diameter ranged from 27 to 139 nm (as measured by the NTA system, Fig. 1B). We next examined EV markers CD9 and CD63 by flow cytometry and western blot. As shown in Fig. 1C, D, the isolated HuMSC-EVs expressed high levels of CD9 and CD63. These findings suggested that EVs were successfully isolated from HuMSCs.

We also tested the internalization of HuMSC-EVs by H9c2 cells. We labeled HuMSC-EVs with PKH-26. After labeling, the HuMSC-EVs pellet showed a strong red color. PKH-26-labeled HuMSC-EVs were then incubated with H9c2 cells. As shown in Fig. 1E, we observed red fluorescence in the cytoplasm in nearly all H9c2 cells, indicating that large amounts of HuMSC-EVs had been taken up by cultured H9c2 cells.

HuMSC-EVs Alleviates H/R Injury

We assessed the viability of H9c2 cells via MTT assay. As shown in Fig. 2A, H/R injury significantly reduced cell viability, as expected, HuMSC-EVs improved cell viability in H9c2 cells subjected to H/R (**P < 0.01 vs control, ***P < 0.01 vs H/R). LDH leakage is widespread use as a marker of cellular damage. According to Fig. 2B, LDH leakage increased in the H/R group compared with the control group, but was significantly decreased by HuMSC-EVs treatment.
These findings revealed that HuMSC-EVs could promote cell survival and alleviate cell damage in H9c2 cells subjected to H/R injury.

**HuMSC-EVs Reduced H/R-Induced ER Stress and Ameliorated H9c2 Cell Apoptosis**

H/R is thought to damage cardiac cells by inducing severe ER stress and apoptosis\(^3\). To confirm the role of HuMSC-EVs in H/R-induced ER stress, the expression of ER stress markers (including GRP78, CHOP, IRE1\(\alpha\), and activating transcription factor 6) were measured by western blot analysis. As expected, levels of all markers investigated were significantly enhanced in the H/R group, indicating increased ER stress during H/R induction. Interestingly, the expression of these markers decreased significantly in the HuMSC-EVs group, compared with the H/R group (Fig. 2C; \(^{**}P < 0.01\) vs control; \(*P < 0.05, **P < 0.01\) vs H/R). To investigate the direct effect of HuMSC-EVs on apoptosis in cardiac cells, the expression levels of Bax, Bel-2, and cleaved-caspase 3 were measured. In the H/R group, Bax and cleaved-caspase 3 were upregulated, while the expression of Bel-2 was downregulated. HuMSC-EVs treatment restored the expression levels of all three proteins to baseline levels in H9c2 cells (Fig. 2H; \(^{**}P < 0.01\) vs H/R). These data show that HuMSC-EVs reduce H/R-induced ER stress and ameliorate apoptosis in cardiac cells.

**HuMSC-EVs Protects Against H/R-Induced ER Stress–Induced Apoptosis Through Activation of the PI3K/Akt Pathway in H9c2 Cells**

Previous studies have shown that the PI3K/Akt pathway is activated by the delivery of exosomes\(^{24,25}\). To further investigate the mechanism by which HuMSC-EVs modulate ER stress, the expression of PI3 K, Akt, and p-Akt in H9c2 cells was measured by western blot analysis. As shown in Fig. 3A, pretreatment with HuMSC-EVs markedly upregulated the expression of PI3 K and p-Akt in H9c2 cells compared with levels observed in the H/R group. Furthermore, a specific inhibitor of PI3K/Akt, LY294002, alleviated the inhibitory effects of HuMSC-EVs on the overexpression of GRP78,
CHOP, IRE1α, and ATF6, suggesting that the inhibition of ER stress by HuMSC-EVs was largely abolished by treatment with LY (Fig. 3D). In addition, the expression of cleaved-caspase 3 was upregulated by cotreatment with LY (Fig. 3D, I). The MTT assay and LDH leakage results suggested that HuMSC-EVs decreased the apoptotic rate in H/R, while the blockade of PI3K/Akt signaling resulted in increased expression of GRP78, CHOP, IRE1α, ATF6, cleaved-caspase 3, and Bax/bcl2 in H9c2 cells.

Discussion

In this study, the effects of HuMSC-EVs on the survival of cardiac cell in response to H/R challenge and the underlying mechanisms were investigated. We found that HuMSC-EVs could protect H9c2 cells against ER stress–induced apoptosis under the stimulation of H/R. The antiapoptotic effect of HuMSC-EVs is partly mediated by the activation of PI3K/Akt signaling through the inhibition of hyperactive ER stress. Severe ER stress was induced by H/R treatment and resulted in increased expression of GRP78, CHOP, IRE1α, and ATF6, which promoted apoptosis in H9c2 cells. Supplementation with HuMSC-EVs attenuated the detrimental effects of H/R in H9c2 cells.
I/R injury is a major cause of morbidity, disability, and mortality worldwide. In recent years, a number of studies have suggested that ER stress–mediated apoptosis plays an important role in the development of MI/R injury. It has been shown that ischemic conditions interrupt ER homeostasis and activate the UPR, which upregulates the expression of various ER stress markers. The images in Figure 3 illustrate the effects of H/R on the expression of PI3K, Akt, and p-Akt, as well as the levels of GRP78, CHOP, IRE1α, ATF6, and cleaved-caspase 3 in H9c2 cells. The Western blot and optical density analysis show significant differences in protein expression following H/R and treatment with HuMSC-EVs and LY294002. 

**Figure 3.** H/R induced ER stress through the activation of PI3K/Akt signaling in H9c2 cells. (A–C) Western blot and optical density analysis for PI3K, Akt, and p-Akt. LY294002 (LY) is a broad-spectrum inhibitor of PI3K/Akt. (D–I) Analysis of protein expression and optical density for GRP78, CHOP, IRE1α, ATF6, and cleaved-caspase 3 in H9c2 cells. (J) H9c2 cell viability. (K) LDH release in H9c2 cells. Values are means ± SD. *P < 0.05, **P < 0.01 H/R vs control; *P < 0.05, **P < 0.01 H/R + HuMSC-EVs vs H/R; ^P < 0.05, ▲P < 0.01 H/R + HuMSC-EVs + LY vs H/R + HuMSC-EVs (n = 3/group). ATF6: activating transcription factor 6; CHOP: C/EBP homologous protein; ER: endoplasmic reticulum; GRP78: glucose-regulated protein 78; H/R: hypoxia/reoxygenation; HuMSC-EVs: human umbilical cord mesenchymal stromal cells derived extracellular vesicles; IRE1α: inositol-requiring protein 1α; LDH: lactate dehydrogenase; SD: standard deviation.
CHOP, a transcription factor. The accumulation of CHOP protein induces the cleavage of caspase-3 and increases the Bax/Bcl-2 ratio, resulting in cell apoptosis. In this study, the expression levels of GRP78, CHOP, IRE1α, and ATF6 were significantly upregulated in H/R-treated H9c2 cells, compared with normal control cells. CHOP overexpression was found to promote the activation of caspase-3 and to increase the Bax/Bcl-2 ratio, thus increasing the rate of apoptosis. These findings suggest that ER stress-mediated apoptosis plays an important role in the development of H/R injury.

EVs secreted by MSCs have been evaluated as a novel therapeutic modality for cardiovascular disease because they protect myocardium against I/R injury. Accumulating evidence has shown that exosomal proteins or RNAs play an important role in modifying the behavior of recipient cells. More importantly, EVs are easy to manipulate and may be transferred between individuals, or even across species. In our study, treatment with HuMSC-EVs ameliorated ER stress, which protected H9c2 cells against excessive apoptosis, suggesting that HuMSC-EVs may effectively inhibit ER stress-mediated apoptosis.

The PI3K/Akt pathway plays a critical role in aspects of cellular physiology such as glucose homeostasis, lipid metabolism, protein synthesis, and cell proliferation and survival. Impairing the PI3K/Akt pathway was found to aggravate ER stress-related apoptosis. In the present study, we observed that H/R-induced ER stress inhibited activation of the PI3K/Akt pathway. The administration of HuMSC-EVs to H9c2 cells restored PI3K/Akt signaling, resulting in a decreased rate of apoptosis. However, the protective effects of HuMSC-EVs were partially eliminated when cells were cotreated with the PI3K/Akt inhibitor LY294002. The expression levels of GRP78, CHOP, IRE1α, ATF6, and cleaved-caspase-3 were all increased when PI3K/Akt signaling was blocked. It is reasonable to speculate that HuMSC-EVs ameliorated ER stress-induced apoptosis through activation of the PI3K/Akt signaling pathway. Although our results indicate that HuMSC-EVs treatment attenuated ER stress–reduced apoptosis in H9c2 cells through activation of the PI3K/Akt pathway, further investigation is required to fully reveal the mechanisms underlying the effects of HuMSC-EVs on ER stress.

In conclusion, we demonstrated that levels of ER stress and cell apoptosis are increased during H/R. HuMSC-EVs may ameliorate ER stress–induced H9c2 cell apoptosis after H/R stimulation in vitro.

Ethical Approval
The study protocol was approved by the Institutional Review Board of Shantou University Medical College (Shantou, China).

Statement of Human and Animal Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Shantou University Medical College (Shantou, China).

Statement of Informed Consent
Informed consent was obtained from all individual participants included in the study.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The present study was supported by grants from the National Natural Science Foundation of China (Grant Nos 81671525 and 81070478), the Science and Technology Program of Shenzhen (Grant Nos JCYJ20150402092905162 and JCYJ20160429141742207), Shenzhen Public Service Platform of Molecular Medicine in Pediatric Hematology and Oncology, Medical Science and Technology Research Foundation of Guangdong Province (Grant No. A2017187), and The Medical and Health Technology Plan Project of Shantou (Grant No. 2018-121).

ORCID iD
Ma Lian https://orcid.org/0000-0002-0736-4582

References
1. Binder A, Ali A, Chawla R, Aziz HA, Abbate A, Jovin IS. Myocardial protection from ischemia-reperfusion injury post coronary revascularization. Expert Rev Cardiovasc Ther. 2015;13(9):1045–1057.
2. Hauserloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92–100.
3. Avril T, Vauleon E, Chevet E. Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis. 2017;6(8):e373.
4. Wu C, Dong S, Li Y. Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload. Int J Mol Med. 2015;35(4):893–900.
5. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011;334(6059):1081–1086.
6. Pihan P, Carreras-Sureda A, Hetz C. BCL-2 family: integrating stress responses at the ER to control cell demise. Cell Death Differ. 2017;24(9):1478–1487.
7. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011;13(3):184–190.
8. Li J, Zhao Y, Zhou N, Li L, Li K. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury in diabetes mellitus by inhibiting endoplasmic reticulum stress. J Diabetes Res. 2019;2019(1):1–12.
9. Shen D, Chen R, Zhang L, Rao Z, Ruan Y, Li L, Chu M, Zhang Y. Sulodexide attenuates endoplasmic reticulum stress induced by myocardial ischaemia/reperfusion by activating the PI3K/Akt pathway. J Cell Mol Med. 2019;23(8):5063–5075.
10. Hass R, Kasper C, Bohm S, Jacobs R. Different populations and sources of human mesenchymal stem cells (MSC): an
comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011;9(12):9–12.

11. Rowart P, Erpicum P, Detry O, Weekers L, Gregoire C, Lechanteur C, Briquet A, Beguin Y, Krzesinski JM, Jouret F. Mesenchymal stromal cell therapy in ischemia/reperfusion injury. J Immunol Res. 2015;2015(10):602597.

12. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton’s Jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther. 2013;8(2):144–155.

13. Zhang C, Zhou G, Chen Y, Liu S, Chen F, Xie L, Wang W, Zhang Y, Wang T, Lai X, Ma L. Human umbilical cord mesenchymal stem cells alleviate interstitial fibrosis and cardiac dysfunction in a dilated cardiomyopathy rat model by inhibiting TNFalpha and TGFbeta1/ERK1/2 signaling pathways. Mol Med Rep. 2018;17(1):71–78.

14. Santos Nascimento D, Mosqueira D, Sousa LM, Teixeira M, Filipe M, Resende TP, Araujo AF, Valente M, Almeida J, Martins JP, Santos JM, et al. Human umbilical cord tissue-derived mesenchymal stem cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms. Stem Cell Res Ther. 2014;5(1):5.

15. Liang X, Ding Y, Zhang Y, Tse HF, Lian Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplant. 2014;23(9):1045–1059.

16. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103(11):1204–1219.

17. Lai RC, Yeo RW, Lim SK. Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 2015;40:82–88.

18. Nawaz M, Fatima F, Vallabhaheni KC, Penfornis P, Valadi H, Ekström K, Kholia S, Whitt JD, Fernandes JD, Pochampally R, Squire JA, et al. Extracellular vesicles: evolving factors in stem cell biology. Stem Cells Int. 2016;2016(10):1073140.

19. Nawaz M, Shah N, Zanetti BR, Maugeri M, Silvestre RN, Fatima F, Neder L, Valadi H. Extracellular vesicles and matrix remodeling enzymes: the emerging roles in extracellular matrix remodeling, progression of diseases and tissue repair. Cells. 2018;7(10):167.

20. Fatima F, Ekstrom K, Nazarenko I, Maugeri M, Valadi H, Hill AF, Camussi G, Nawaz M. Non-coding RNAs in mesenchymal stem cell-derived extracellular vesicles: deciphering regulatory roles in stem cell potency, inflammatory resolve, and tissue regeneration. Front Genet. 2017;8:161.

21. Wang C, Zhu G, He W, Yin H, Lin F, Gou X, Li X. BMSCs protect against renal ischemia-reperfusion injury by secreting exosomes loaded with miR-199a-5p that target BIP to inhibit endoplasmic reticulum stress at the very early reperfusion stages. FASEB J. 2019;33(4):5440–5456.

22. Wang B, Zhong S, Zheng F, Zhang Y, Gao F, Chen Y, Lu B, Xu H, Shi G. N-n-butyl haloperidol iodide protects cardiomyocytes against hypoxia/reoxygenation injury by inhibiting autophagy. Oncotarget. 2015;6(28):24709–24721.

23. Li YP, Wang SL, Liu B, Tang L, Kuang RR, Wang XB, Zhao C, Song XD, Cao XM, Wu X, Yang PZ, et al. Sulforaphane prevents rat cardiomyocytes from hypoxia/reoxygenation injury in vitro via activating SIRT1 and subsequently inhibiting ER stress. Acta Pharmacol Sin. 2016;37(3):344–353.

24. Pan Q, Wang Y, Lan Q, Wu W, Li Z, Ma X, Yu L. Exosomes derived from mesenchymal stem cells ameliorate hypoxia/reoxygenation-injured ECs via transferring MicroRNA-126. Stem Cells Int. 2019;2019:2831756.

25. Liu H, Sun X, Gong X, Wang G. Human umbilical cord mesenchymal stem cells derived exosomes exhibit antiapoptosis effect via activating PI3K/Akt/mTOR pathway on H9C2 cells. J Cell Biochem. 2019;120(9):14455–14464.

26. Wu D, Wang J, Li H, Xue M, Ji A, Li Y. Role of hydrogen sulfide in ischemia-reperfusion injury. Oxid Med Cell Longev. 2015;2015:186908.

27. Fang SJ, Li PY, Wang CM, Xin Y, Lu WW, Zhang XX, Zuo S, Ma CS, Tang CS, Nie SP, Qi YF. Inhibition of endoplasmic reticulum stress by neuregulin-1 protects against myocardial ischemia/reperfusion injury. Peptides. 2017;88:196–207.

28. Guo C, Zhang J, Zhang P, Si A, Zhang Z, Zhao L, Lv F, Zhao G. Ginkgolide B ameliorates myocardial ischemia reperfusion injury in rats via inhibiting endoplasmic reticulum stress. Drug Des Devel Ther. 2019;13:767–774.

29. Omidkhoda N, Hayes AW, Reiter RJ, Karimi G. The role of MicroRNAs on endoplasmic reticulum stress in myocardial ischemia and cardiac hypertrophy. Pharmacol Res. 2019;150:104516.

30. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998;12(7):982–995.

31. Go BS, Kim J, Yang JH, Choe ES. Psychostimulant-induced endoplasmic reticulum stress and neurodegeneration. Mol Neurobiol. 2017;54(6):4041–4048.

32. Rodriguez D, Rojas-Rivera D, Hetz C. Integrating stress signals at the endoplasmic reticulum: the BCL-2 protein family rheostat. Biochim Biophys Acta. 2011;1813(4):564–574.

33. Huang L, Ma W, Ma Y, Feng D, Chen H, Cai B. Exosomes in mesenchymal stem cells, a new therapeutic strategy for cardiovascular diseases? Int J Biol Sci. 2015;11(2):238–245.

34. Rani S, Ryan AE, Griffin MD, Ritter T. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther. 2015;23(5):812–823.

35. Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Rosenzag M, Matthay MA, Lee JW. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med. 2015;192(3):324–336.

36. Huang X, Liu G, Guo J, Su Z. The PI3K/Akt pathway. Life Sci. 2019;224:149–156.